To account for the complicated relationship between C3, FH, age, diagnosis, and established CSF AD biomarkers, we used XMITTN to determine if the introduction of C3 and FH levels into a two-class classification model can enhance the distinction between MCI and mild AD. The gene discussed is C3; the disease is Alzheimer disease.